Performance of dexamethasone coated polyvinyl chloride pipeline in the extracorporeal circulation

doi:10.3969/j.issn.2095-4344.2013.12.013

Abstract

Abstract:

BACKGROUND: Dexamethasone as coating is fixed to the surface of cardiopulmonary bypass pipe, which can maintain sustainable anti-inflammatory effects and avoid adverse reactions due to excessive blood concentration, thereby maximizing the anti-inflammatory action of dexamethasone.
OBJECTIVE: To develop a new coating method of dexamethasone sodium phosphate, which has anticoagulation activity, and to evaluate the performance of the coated pipeline, including the stability, anticoagulant and antiplatelet activity.
METHODS: The surface of polyvinyl chloride pipelines in the extracorporeal circulation was successively pretreated with strong sulfuric acid and polyethylene imines. Dexamethasone sodium phosphate coated pipelines were made through two methods: ionic blond and premix. Then, a quantitative analysis was performed to evaluate anticoagulation, antiplatelet, resistance of protein adhesion and antithrombosis function. Non-coated polyvinyl chloride pipeline served as control group.
RESULTS AND CONCLUSION: The biggest drug loadings were (2.06 ±0.68) and (3.33±0.75) μg/cm²for dexamethasone sodium phosphate coated polyvinyl chloride pipelines prepared by premix and ionic blond, respectively. In the anticoagulation, antiplatelet, and resistance of protein adhesion experiment, dexamethasone sodium phosphate coated polyvinyl chloride pipelines prepared by premix were superior to those prepared by ionic blond and control group (P < 0.05). Release in vitro experiment showed that dexamethasone sodium phosphate coated polyvinyl chloride pipelines prepared by premix were also superior to those prepared by ionic blond. The findings indicate that the dexamethasone sodium phosphate coating prepared by premix shows better release and anticoagulation performance, as well as forms antiplatelet adhesion and antithrombosis function, to meet the short-term extracorporeal circulation requirements.

Key words: biomaterials, biomaterials and controlled drug release, dexamethasone sodium phosphate, sodium alginate, polyvinyl chloride, slow-release, coating, biocompatibility, other grants-supported paper, biomaterial photographs-containing paper

CLC Number:

R318

Yu Guang-dong, Li Tong, Gao Wen-qing, Yu Mei-li, Zhou Shu-fen, Lu Hai-bin, Li Jin-you. Performance of dexamethasone coated polyvinyl chloride pipeline in the extracorporeal circulation[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(12): 2177-2184.

Figures/Tables 8

References

[1] Goulding NJ.The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus.Curr Opin Pharmacol. 2004;4(6):629-636.

[2] Beato M,Herrlich P,Schutz G.Steroid hormone receptors: many actors in search of a plot.Cell.1995;83(6):851-857.

[3] Kirklin JK.The postperfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass[A].In: Tinker JH(ed):cardiopulmonary bypass: current concept and controversies.Philadelphia:W.B.Saunders,1989:131-146.

[4] Replogle RL,Gazzaniga AB,Gross RE.Use of corticosteroid during cardiopulmonary bypass: possible lysosome stabilization.Circulation.1996;33(4 suppl I):86-92.

[5] Wu C,Zhu Y,Chang J,et al. Bioactive inorganic-materials/ alginate composite microspheres with controllable drug-delivery ability. J Biomed Mater Res B Appl Biomater. 2010;94(1):32-43.

[6] Luo X,Matranga C,Tan S,et al.Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone.Biomaterials.2011;32(26):6316-6323.

[7] Fratoddi I,Venditti I,Cametti C, et al.Functioonal polymeric nanoparticles for dexamethsone loading and release. Colloid Surf B Biointerfaces.2012;5(93):59-66.

[8] Chen YP,Wang GX,Chen Y,et al.Disan Junyi Daxue Xuebao. 2008;30(10)：935-937. 陈勇鹏,王贵学,陈琰,等.地塞米松血管内支架的涂层制备及体外缓释实验研究[J].第三军医大学学报,2008,30(10)：935-937.

[9] Fan Y,Yao J,Zhou JP.Gaodeng Xuexiao Huaxue Xuebao. 2011;32(12)：2916-2922. 范颖,姚静,周建平.细胞核靶向聚乙烯亚胺-地塞米松偶联物的制备及作为基因载体的应用[J].高等学校化学学报,2011,32(12)：2916-2922.

[10] Yii M,Gourlay T,Fleming J,et al. Evaluation of Carmeda bioactive surface (CBAS), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass.Perfusion.1996;11(3): 229-240.

[11] Le-Tien C,Millette M,Lacroix M,et al.Modified alginate matrices for the immobilization of bioactive agents.Biotech Appl Biochem.2004;39(Pt2):189-198.

[12] Lee JH,Ju YM,Kim DM.Platelet adhesion onto segmented polyurethane film surfaces modified by addition and crosslinking of PEO-containing block copolymers. Biomaterials. 2000;21(7):683-691.

[13] Smith PK,Krohn RI,Hermanson GT,et al.Measurement of protein using bicinchoninic acid.Anal Biochem.1985;150(1): 76-85.

[14] Chandler AB.An examination of the fluid mechanics and thrombus formation time parameters in a Chandler rotating loop system.J Lab Clin Med.1974;84(4):494-507.

[15] Guo QK,Lu ZQ,Wang JY,et al.In vivo evaluation of a novel dexamethsaone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. J Mater SCI Mater Med. 2011;22(6):1615-1623.

[16] Ribichini F,Tomai F,Paloscia L,et al. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart.2007;93(5):598-600.

[17] Soares LC,Ribas D,Spring R,et al.Clinical profile of systemic inflammatory response after pediatric cardiac surgery with cardiopulmonary bypass. Arq Bras Cardiol.2010;94(1): 127-133.

[18] Liou HL,Shih CC,Chao YF,et al.Inflammatory respose to colloids compared to crystalloid priming in Cardiac surgery patients with cardiopulmonary bypass. Chin J Physio.2012; 55(3):210-218.

[19] Heying R,Wehage E,Schumacher K,et al.Dexamethasone pretreatment provides antiinflammatoty and myocardial protection in neonatal arterial switch operation. Ann Thorac Surg.2012;93(3):869-876.

[20] Cappabianca G,Rotunno C,De Luca Tuppti Schinosa L,et al.Protetective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials.J Cardiothorac Vasc Anesth.2011;25(1):156-165.